Efficacy and safety of inhaled human insulin (Exubera®) compared to subcutaneous insulin in children ages 6 to 11 years with type 1 diabetes mellitus: Results of a 3-month, randomized, parallel trial

Journal of Pediatric Endocrinology and Metabolism

Volumn 21, Issue 6, 2008, Pages 555-568

  White, Neil H ^a   Quattrin, Teresa ^b   St Aubin, Lisa B ^c   Duggan, William T ^c   England, Richard D ^c   Fryburg, Julie S ^c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Glycemic control; Hypoglycemic events; Inhaled insulin; Pediatrics; Type 1 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN ANTIBODY; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LONG ACTING INSULIN; RECOMBINANT HUMAN INSULIN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER;

ABDOMINAL PAIN; ASTHENIA; BEDTIME DOSAGE; CARDIOVASCULAR SYMPTOM; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; FLU LIKE SYNDROME; GLYCEMIC CONTROL; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION SITE PAIN; INSULIN DEPENDENT DIABETES MELLITUS; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; NAUSEA; OTITIS MEDIA; PARALLEL DESIGN; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINITIS; SEIZURE; SINGLE DRUG DOSE; SINUSITIS; SKIN HYPERTROPHY; TREMOR; BLOOD; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; IMMUNOLOGY; INHALATIONAL DRUG ADMINISTRATION; MALE; PATHOLOGY; PROGNOSIS; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; ALGORITHMS; ANTIBODIES; BLOOD GLUCOSE; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN; LUNG; TREATMENT OUTCOME; BIOMARKERS; FEMALE; FOLLOW-UP STUDIES; HYPOGLYCEMIC AGENTS; INSULIN ANTIBODIES; MALE; PROGNOSIS;

EID: 48449104492     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. Rave K, Becker RHA, Bott S, Willavize SA, Heinemann L, Heise T, Sha S. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 2005; 28: 1077-1082.
2. Strack TS. Inhaled human insulin. Drugs of Today 2006; 42: 207-221.
3. Quattrin T, Schwartz SI, Belanger A, Bohannon NJV, for the Exubera Phase III Study Group. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in subjects with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004; 27: 2622-2627.
4. Hollander PA, Mershon KS, Blonde L, Chiasson J-L, Rowe R, Levin SR, Mehta AE, Milburn JL, for the Exubera Phase III Study Group. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in subjects with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004; 27: 2356-2362.
5. Rosenstock J, Bolinder B, Cappelleri JC, Gerber RA. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in subjects with type 1 or type 2 diabetes. Diabetes Care 2004; 27: 1318-1323.
6. de Fronzo RA, Lerman S, Bergenstal RM, Bode BW, Cefalu WT, Phillips LS, Pullman J, for the Exubera Phase III Study Group. Efficacy of inhaled insulin in subjects with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care 2005; 28: 1922-1928.
7. Barnett AM, Serdarevic-Pehar M, Dreyer M, Lange P, on behalf of the Exubera Phase III Study Group. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in subjects with type 2 diabetes poorly controlled on metformin. Diabetes Care 2006; 29: 1818-1825.
8. Skyler JS, Jovanovic L, Klioze S, Reis J, Duggan W. Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes mellitus. Diabetes Care 2007; 30: 579-585.
9. Rosenstock J, Foyt H, Klioze S, Masayo O, St Aubin L, Duggan W. Inhaled human insulin (txubera) therapy shows sustained efficacy and is well tolerated over a 2-year period in patients with type 2 diabetes (T2DM). Diabetes 2006; 55 (Suppl 1): A26.
10. Dreyer M, for the Exubera Phase 3 Study Group. Efficacy and 2-year pulmonary safety data of inhaled insulin as adjunctive therapy with metformin or glibenclarnide in type 2 diabetes: patients poorly controlled with oral monotherapy. Diabetologia 2004; 47 (Suppl 1): A44.
11. Teeter JG, Reise RJ. Dissociation iof lung function changes with humoral immunity during inhaled human insulin therapy. Am J Respir Crit Care Med 2006; 173: 1194-1200.
12. Norwood P, Dumas M, Cefalu W, Yale J-F, England RD, Riese RJ, Teeter J, for the Exubera® Phase 3 Study Group. Randomized study to characterize glycemic control and short-term pulmonary function in patients with type 1 diabetes receiving inhaled human insulin (Exubera®). J Clin Endocrinol Metab 2007; 92: 2211-2214.
13. Elliott RB, Edgar BW, Pilcher CC, Quested C, McMaster J. Parenteral absorption of insulin from the lung in diabetic children. Aust Paediatr J 1987; 23: 293-297.
14. Skyler JS, Gerich JE, Weinstock RS, Gerstein HC, Raskin P, Yale J-F, Barrett E, for the Inhaled Insulin Phase III Type 1 Diabetes Study Group. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care 2005; 28: 1630-1635.
15. Porter PA, Keating B, Byrne G, Jones TW. Incidence and predictive criteria of nocturnal hypoglycemia in young children with insulin-dependent diabetes mellitus. J Pediatr 1997; 130: 366-372.
16. Boland EA, Brandt CA, Monsod T, Fernando S, Delucia M, Tamborlane WV. Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric subjects with type 1 diabetes. Diabetes Care 2001; 24: 1858-1862.
17. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1998; 21 (Suppl 1): 5-19.
18. Hammer LD, Kraemer HC, Wilson DM, Ritter PL, Dornbusch SM. Standardized percentile curves of body mass index for children and adolescents. Am J Dis Child 1991; 145: 259-263.
19. American Diabetes Association: Diabetes mellitus and exercise. Diabetes Care 1998; 21 (Suppl 1): 40-44.
20. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
21. American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 1995; 152: 1107-1135.
22. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor): recommendations for a standard technique: 1995 update. Am J Respir Crit Care Med 1995; 152: 2185-2198.
23. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Statist 1982; 10: 1100-1120.
24. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Statist Assoc 1989; 84: 1074-1078.
25. Exubera® [US package insert]. New York, NY: Pfizer Inc, 2006.
26. Fineberg SE, Kawabata T, Finco-Kent D, Liu C, Krasner A. Antibody response to inhaled insulin in subjects with type 1 or type 2 diabetes: an analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J Clin Endocrinol Metab 2005; 90: 3287-3294.
27. Hollander P, Skyler J, Jovanovic L, Klioze S, Krasner A, Riese R, Reis J, Schwartz P. Pulmonary safe following discontinuation and readministration of inhaled human insulin (Exubera®) in adults with type 1 diabetes. Diabetes 2007; 56 (Suppl 1): A25-A26.